-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Both camrelizumab (Erica) and chemotherapy as first-line therapy in patients with advanced esophageal squamous cell carcinoma (ESCC) have shown durable antitumor activity and manageable safety profiles
.
This study aimed to evaluate the efficacy and safety of camrelizumab combined with neoadjuvant chemotherapy in the treatment of locally advanced ESCC
Patients with locally advanced but surgically resectable thoracic esophageal squamous cell carcinoma with stage T1b-4a, N2-3 (≥ level 3), M0, or M1 lymph node metastases (limited to supraclavicular lymph nodes) were recruited
.
Two courses of study treatment were given before surgery, 21 days as a course, with a regimen of camrelizumab (200 mg) and carboplatin on day 1 of each course, and on days 1/8/15 nab-paclitaxel (100 mg/m 2 )
Camrelizumab (200 mg) and carboplatin were administered on day 1 of each cycle, and nab-paclitaxel (100 mg/m 2 ) was administered on days 1/8/15
Pathological response in 51 patients
Pathological response in 51 patientsA total of 60 patients were enrolled between November 20, 2019, and December 22, 2020
.
Fifty-five (91.
Twenty (39.
Treatment-Related Adverse Reactions
Treatment-Related Adverse ReactionsFifty-eight (96.
7%) patients experienced any grade of treatment-related adverse events (TRAEs), the most common of which was leukopenia (86.
7%)
.
Thirty-four (56.
In conclusion, this study demonstrated the strong antitumor activity of camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety issues
.
Combination regimen of camrelizumab with chemotherapy is a promising neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
Robust antitumor activity of camrelizumab in combination with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety concerns
Original source:
Original source:Liu Jun,Yang Yang,Liu Zhichao et al.
Liu Jun,Yang Yang,Liu Zhichao et al.
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
[J] .
J Immunother Cancer, 2022, 10: https:/ /doi.
org/10.
1136/jitc-2021-004291.
Leave a message here